The coming revolution in applications of genetics offers more value creation potential than almost any other venture category.
Gene tech startups aim to cure many of the most agonizing and expensive diseases, improving happiness and reducing healthcare needs. Other gene tech startups will enable plants and microbes to produce newer and better things while sustaining the natural environment.
Lexi Ventures seeks diversification across health, consumer products, materials, and other sectors. We invest around seed stage in US companies involved with DNA, RNA, cells, and omics.
Lexi Ventures provides seed and pre-seed stage funding for US-based startups applying or enabling gene tech or syn bio.
Our key words are DNA, RNA, cell, 'omics.
Please connect if you are working on any of these.
A novel type of cell or gene therapy
Diagnostics using DNA, RNA, or proteins
Genetically engineered plants or microbes
Related software, chemistry, or devices
Lexi Ventures tends not to invest in
Small molecules
Single therapeutic assets
Medical devices
Consumer-facing software
Jonah was a top-25 gene tech investor in 2024.
Before founding Lexi Ventures, Jonah held founder, executive, and engineering roles in 7 startups. He achieved 2 IPOs, 16 granted patents and wrote 2 books. He has a lifelong interest in science, engineering, economics, philosophy, and innovation.
Jonah is known for:
Transparency and honesty
Contrarian thinking
A patient approach to investing